Get the latest news, insights, and market updates on GSK (GSK plc). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Assessing GSK (LSE:GSK) Valuation After Strong Recent Share Momentum
Recent share performance and business backdrop Without a clear single news catalyst, GSK (LSE:GSK) has still been on many investors’ radars, helped by its recent share performance and the scale of its global pharmaceuticals and vaccines business. The stock shows positive returns over the past day, week, month and past 3 months, alongside a 1 year total return of 53.83% and a 3 year total return of 63.74%, based on the data provided. See our latest analysis for GSK. At a share price of £21.8,... Feb 6, 2026 - $GSK
GSK RSV Vaccine Wins EU Adult Approval As Shares Trade Above Targets
GSK's RSV vaccine Arexvy has received European Commission approval for use in adults aged 18 and over. The decision expands eligibility beyond the previous focus on adults aged 60+ and those at higher risk. The broader label significantly enlarges the potential patient pool for Arexvy across European markets. LSE:GSK now has a materially wider opportunity for its RSV franchise in Europe, with Arexvy cleared for all adults from 18 upwards. The move comes as GSK shares trade around £21.8,... Feb 5, 2026 - $GSK
GSK beat the numbers, but the real story was the guidance
A clean fourth-quarter beat pushed GSK ahead of its own medium-term targets. Yet management chose to set a deliberately modest bar for 2026, leaving investors to decide whether this is prudence or opportunity. At first glance, GSK PLC's (LSE:GSK, NYSE:GSK) fourth-quarter results look like... Feb 4, 2026 - $GSK
GSK delivers solid 2025 results, reaffirms growth outlook for 2026
Specialty Medicines drive strong sales as company maintains guidance and raises dividend GSK PLC (LSE:GSK, NYSE:GSK) reported a 7% rise in sales for 2025 to £32.7 billion, led by strong performance in Specialty Medicines, which grew 17% to £13.5 billion. Sales in HIV, Oncology and... Feb 4, 2026 - $GSK
GSK Q4 Earnings Call Highlights
GSK (NYSE:GSK) executives struck an upbeat tone on the company’s full-year 2025 results call, pointing to broad-based sales growth, operating leverage, and a pipeline they said is gaining momentum. Management also outlined priorities for 2026 centered on maximizing key launches, accelerating late-st Feb 4, 2026 - $GSK
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple